BSD gets breast cancer therapy patent from Duke:
This article was originally published in Clinica
BSD Medical has signed an exclusive patent licence agreement for rights to Duke University's hyperthermia treatment for primary breast cancer. The Salt Lake City, Utah-based firm intends to integrate the technology with its current BSD-2000 and BSD-500 hyperthermia systems. The treatment will be used to complement radiation therapy, chemotherapy and heat-released, targeted liposome drug delivery. BSD claims that the potential to treat breast cancer with hyperthermia therapy has been boosted by trials at the Durham, North Carolina university. Studies have shown that patients receiving radiation therapy in conjunction with hyperthermia have a greater chance of complete response compared with those receiving radiotherapy alone.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.